Canadian Cancer Trials Group Bulletins


OICR at Canadian Cancer Trials Group to Announce $12.6M for HICT

Ontario Minister of Consumer Affairs and MPP for Kingston and the Islands, John Gerretsen, and Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), were at the Canadian Cancer Trials Group on Monday, August 22 to officially announce $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

The HICT Program, led by Dr. Janet Dancey, who is also Director of Clinical Translational Research at Canadian Cancer Trials Group, will introduce more translational research into clinical trials, ensuring the best research discoveries are developed into new approaches for treating cancer patients. The Program has been designed to evaluate innovative technologies that will lead to more personalized medicine, offering more targeted treatment potentially associated with greater efficacy and less toxicity.
The press conference highlighted one of the major projects within the High Impact Clinical Trials Program, the Rare Tumours Clinical Trial initiative, which aims to better integrate recent advances in genomics research into regular clinical practice.

The Rare Tumour Clinical Trials Initiative is a partnership between OICR, Pfizer Canada, and the Canadian Cancer Trials Group, and brings together a multidisciplinary team of clinical investigators, pathologists and genomics researchers to investigate new solutions to treating rare tumours. As part of this initiative, the Canadian Cancer Trials Group┐s New Investigational Drug Program is conducting IND.206 -- A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours. Due to their infrequency rare cancers are still quite poorly understood, severely limiting current treatment options for patients with these cancers. However, recent advances in genomics technology offer hope that better treatment options resulting from this initiative may be achieved within five years. IND.206 incorporates deep genomic sequencing, which will be conducted in a correlative project based at OICR and an innovative "umbrella" trial design that permits patients with different forms of rare cancers to be eligible and serves as a template for future trials testing treatment options for other rare cancers.

The announcement also highlighted a Princess Margaret Hospital Consortium Genomics Cohort Study that is led by Dr. Lillian Siu.

The announcement was covered by multiple media outlets, including the CBC.
Please follow this link: